Best Nanotechnology Stocks To Add to Your Watchlist - August 5th

Key Points

• Seven notable nanotechnology stocks to watch include Onto Innovation, OSI Systems, Nano Dimension, and Biodexa Pharmaceuticals, which have shown the highest trading volumes recently.
• Nanotechnology stocks are seen as having high growth potential but also come with significant volatility and technological risks due to the emerging nature of the field.
• Companies like Clene and NVE are involved in innovative therapeutic solutions and spintronics technology, reflecting the diverse applications of nanotechnology across sectors.

Onto Innovation, OSI Systems, Nano Dimension, NVE, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose primary business involves the research, development, manufacturing or commercialization of materials and devices engineered at the nanoscale (typically 1–100 nanometers). Investors buy these equities to gain exposure to firms working on applications such as targeted drug delivery, advanced electronics, and novel materials. Because the field is still emerging, these stocks can exhibit higher growth potential along with greater volatility and technological risk. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

Shares of NYSE:ONTO traded down $2.08 during trading on Tuesday, reaching $95.12. The stock had a trading volume of 536,919 shares, compared to its average volume of 1,219,080. The firm's fifty day moving average is $98.23 and its 200 day moving average is $125.88. Onto Innovation has a 52 week low of $85.88 and a 52 week high of $228.42. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of 21.52, a P/E/G ratio of 0.61 and a beta of 1.44.

Read Our Latest Research Report on ONTO

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ:OSIS traded down $3.05 during trading on Tuesday, reaching $218.65. The stock had a trading volume of 71,027 shares, compared to its average volume of 223,365. The firm's fifty day moving average is $222.38 and its 200 day moving average is $208.36. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.38 and a current ratio of 2.11. OSI Systems has a 52 week low of $129.84 and a 52 week high of $241.64. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of 26.60, a P/E/G ratio of 1.86 and a beta of 1.31.

Read Our Latest Research Report on OSIS

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Shares of NASDAQ:NNDM traded down $0.01 during trading on Tuesday, reaching $1.39. The stock had a trading volume of 1,045,826 shares, compared to its average volume of 2,086,590. The stock has a market cap of $300.93 million, a price-to-earnings ratio of -3.46 and a beta of 1.13. Nano Dimension has a 52 week low of $1.34 and a 52 week high of $2.74. The firm's fifty day moving average is $1.51 and its 200 day moving average is $1.78.

Read Our Latest Research Report on NNDM

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NASDAQ NVEC traded down $0.32 on Tuesday, hitting $59.87. 13,586 shares of the company were exchanged, compared to its average volume of 43,669. The company has a market cap of $289.75 million, a PE ratio of 19.96 and a beta of 1.19. NVE has a 12 month low of $51.50 and a 12 month high of $88.50. The stock has a fifty day moving average of $72.36 and a 200-day moving average of $68.52.

Read Our Latest Research Report on NVEC

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

NASDAQ BDRX traded down $0.01 on Tuesday, hitting $6.98. 25,683 shares of the company were exchanged, compared to its average volume of 192,253. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $9.46 and a 200-day moving average of $19.44. Biodexa Pharmaceuticals has a 12 month low of $5.85 and a 12 month high of $163.10.

Read Our Latest Research Report on BDRX

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN traded up $0.01 during trading on Tuesday, hitting $3.75. 27,084 shares of the company's stock were exchanged, compared to its average volume of 72,896. The business's 50 day moving average is $3.84 and its two-hundred day moving average is $3.74. Clene has a fifty-two week low of $2.28 and a fifty-two week high of $6.96. The stock has a market cap of $30.97 million, a P/E ratio of -0.93 and a beta of 0.55.

Read Our Latest Research Report on CLNN

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNNW stock traded down $0.00 on Tuesday, hitting $0.04. The stock had a trading volume of 1,600 shares, compared to its average volume of 10,602. The business has a 50 day moving average of $0.03 and a 200 day moving average of $0.03. Clene has a 12-month low of $0.02 and a 12-month high of $0.08.

Read Our Latest Research Report on CLNNW

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.